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Pulmonary dysfunction is a common complication of cardiac surgery.Themechanisms involved in the development of pulmonary
dysfunction are multifactorial and can be related to the activation of inflammatory and oxidative stress pathways. Clinical
manifestation varies from mild atelectasis to severe respiratory failure. Managing pulmonary dysfunction postcardiac surgery is a
multistep process that starts before surgery and continues during both the operative and postoperative phases. Different pulmonary
protection strategies have evolved over the years; however, the wide acceptance and clinical application of such techniques remain
hindered by the poor level of evidence or the sample size of the studies. A better understanding of available modalities and/or
combinations can result in the development of customised strategies for the different cohorts of patients with the potential to hence
maximise patients and institutes benefits.
1. Introduction
Pulmonary dysfunction is a common complication of cardiac
surgery that can impact patient’s outcomes and health eco-
nomics. It is recognised that many patients will have altered
pulmonary mechanics after surgery which may appear in a
wide range of clinical presentations, from mild atelectasis to
life threatening acute lung injury (ALI) or adult respiratory
distress syndrome (ARDS) [1–3].
Surgical incisions by abolishing the integrity of the
chest wall affect respiratory mechanics leading to impaired
respiratory effort. Postoperative pain has been shown to
be associated with decreased lung function by precluding
deep inspirations. Furthermore, patients undergoing surgical
procedures associated with opening the pleura will have
increased rates of atelectasis, pleural effusions, and postoper-
ative pain especially in the early postoperative period [4–6].
Cardiopulmonary bypass (CPB) can lead to the activation
of different inflammatory and coagulation pathways and
alters redox balance due to the passage of blood through the
circuit (contact activation) and ischaemia and reperfusion
injury [7–10].
Vascular endothelial cells (EC) dysfunction during CPB
due to changes in blood flow patterns, shear stress, ischaemia,
and reperfusion and circulating cytokines will result in the
activation of multiple proinflammatory and proapoptosis
pathways [11–14] while suppressing its ability to produce
vasoprotective mediators [14–17]. EC activation is known
to initiate leukocytes adhesion cascade by the expression of
members of the selectin family which are responsible for
the initial attachment of leukocytes from circulation. Trans-
migration of leukocyte through EC (crucial step for leuko-
cytes recruitment to tissue) follows leukocytes attachment
and is mediated by the upregulation of different adhesion
molecules such as platelet endothelial cell adhesionmolecule-
(PECAM-) 1, ICAM-1, and very late antigen-4 (VLA-4) [18–
21].
CPB is traditionally associated with inadequate lung
perfusion as there is no flow to the pulmonary artery
during periods of cross clamping and when the heart is
not ejecting blood, and thus blood supply is limited to
the bronchial arteries [22]. Pulmonary physiology alteration
during CPB can result in disturbing the balance in the
blood gas barrier due to the alteration of the different force
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 416235, 8 pages
http://dx.doi.org/10.1155/2015/416235
2 Oxidative Medicine and Cellular Longevity










Figure 1: Mechanisms involved in pulmonary dysfunction during
cardiac surgery and its consequences.
affecting the parenchyma thus abolishing gas exchange by
passive diffusion at the blood-gas barrier level and leading
to ventilation/perfusion mismatch and impaired pulmonary
compliance [23, 24]. Moreover, ischaemia during CPB is
associated with reduced alveolar blood supply resulting in
alveolar ischaemia and hypoxic pulmonary vasoconstriction
[25]. Pulmonary vascular endothelial cells dysfunction and
activated neutrophils sequestration into lungs parenchyma
during period of reperfusion can increase lung tissue per-
meability and elevate vascular resistance and pulmonary
surfactant changes leading to alveolar protein accumulation
and pulmonary oedema and drivingmore ROS and cytokines
production [26–28]. This will be manifested as abnormal gas
exchange, poor lung mechanics, increased pulmonary shunt
fraction and reduced functional residual capacity, and carbon
monoxide transfer factor [28–30] (Figure 1).
Blood and blood products usage after surgery can be
associated with the production of excessive amount of ROS
and systemic and pulmonary inflammation. It has been previ-
ously shown that the duration of blood storage before transfu-
sion can influence adverse effect associated with transfusion
as there are an increased risk of respiratory insufficiency and
the need for prolonged ventilation in patients receiving blood
stored for longer than two weeks [10, 31–34].
Here we review the most commonly used strategies to
minimise pulmonary dysfunction after cardiac surgery.
2. Pulmonary Protection Strategies
2.1. Pharmacological Interventions. The fact that inflamma-
tion andoxidative stress play a pivotal role in the development
of pulmonary dysfunction resulted in multiple studies aimed
toward modulating such events by the administration of
vasodilators and antioxidant and anti-inflammatory medica-
tions in experimental animal models or patients undergoing
cardiac surgery.
Prostacyclins can induce vascular smooth muscle cells
relaxation by the release of intracellular adenosine 3󸀠,5󸀠
cyclic monophosphate (cAMP) resulting in pulmonary and
systemic vasodilation [35–38]. Moreover, they can have
inhibitory effect on platelet aggregation and leukocytes and
monocytes activity [39]. The use of inhaled prostacyclins
(Epoprostenol or Flolan) has been shown to decrease pul-
monary arterial endothelial dysfunction induced by CPB in
experimental studies [40–42]. Furthermore, when adminis-
tered prior to CPB, they can have beneficial effect in the
presence of pulmonary hypertension and may result in lower
rate of reintubation in high risk postoperative cardiac patients
[43, 44].
Phosphodiesterase inhibitors such as pentoxifylline
(PTX) which is a known nonselective phosphodiesterase
(PDE) inhibitor can result in elevated levels of intracellular
cAMP and vasodilatation. Although PTX has been used
classically for claudication symptoms in peripheral vascular
disease [45], it has been shown to exert anti-inflammatory
and antioxidative properties resulting in modulation of ALI
[46–48].More selective PDE inhibitors such asmilrinone can
be an advantageous therapeutic strategy for cardiac surgical
patients with increased pulmonary vascular resistance (PVR)
and right ventricular failure when nebulized and inhaled. It
can cause selective pulmonary vasodilation and potentiate
the vasodilation effects of inhaled prostacyclin [49, 50].
Nitric oxide (NO) is known to play a pivotal role in
vascular endothelial cells homeostasis and regulation of
oxidative stress and inflammatory responses [51]. Ischaemia
and reperfusion injury during surgery is associated with
significant loss in NO; thus NO preconditioning has been
suggested to reduce perioperative pulmonary dysfunction
and its sequels [52–54]. The protective effects may be due to
reversal of postischemic lung hypoperfusion and reduction of
lung neutrophil sequestration. The administration of NO in
patients with severe left ventricular dysfunction can lead to
pulmonary vasodilatation and may augment left ventricular
filling [55–57]. The timing of administration and/or con-
centration of inhaled NO during ischaemia or reperfusion
periods is a very important determinant of its effect as NO
is toxic early in reperfusion, due to its interaction with
superoxide which may lead to damage of alveolar type 2 cells
[58, 59].
A large number of other drugs have been used with
various degrees of success. Aprotinin (serine proteases) had
been shown to reduce neutrophil elastase, malondialdehyde,
and proinflammatory cytokines levels in bronchoalveolar
lavage fluids of patients undergoing cardiac surgery [60].The
use of aprotinin can result in improving lung function and
reducing reperfusion lung injury [61]. The administration
of corticosteroids before CPB may reduce the activation
of multiple proinflammatory mediators. The translation of
proinflammatory mediator’s changes into clinical outcomes
remains controversial and most of the evidence in the
literature originates from small RCTs or observational studies
with biomarkers as primary end points [62, 63].
2.2. CPB Modification. Different strategies have been
attempted over the years to minimise proinflammatory
activation and oxidative stress when using CPB such as
coating the circuit with biocompatible material (heparin,
poly-2-methoxyethyl acrylate, synthetic protein, and phos-
phorylcholine), removal of leukocytes (by adding special
filters to theCPB), ultrafiltration, andreduced haemodilution.
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Heparin is thought to reduce the inflammatory responses
linked to platelets and leukocytes by reducing the release of
IL-6, IL-8, E-selectin, lactoferrin, myeloperoxidase, integrin,
selectin, and platelet thromboglobulin and decreasing the
production of oxygen free radicals [64–66]. It has been
suggested that compared with conventional circuits (poly-
2-methoxyethyl acrylate, synthetic protein, and phospho-
rylcholine), the heparin-coated circuit may improve lung
compliance and pulmonary vascular resistance and thus
reduce intrapulmonary shunt although intubation time and
ICU stay were not affected [67, 68].
The use of leukocyte filtration mechanisms can modulate
proinflammatory cytokines and oxidative stress [69–71]. A
clinical study compared the effectiveness of leukocyte filter
depletion with a common arterial filter in CABG patients
who reported better oxygenation indices and less duration
of postoperative mechanical ventilation in the leukocyte
depletion filter group [71]. Another study suggested that
leukocyte depletion filters preferentially remove activated
leukocytes. Improvement in lung function was evident only
in the early postoperative phase, but this did not lead to
decreasing mortality or better clinical outcomes [72]. The
use of ultrafiltration or modified ultrafiltration techniques
at the end of surgery may reduce postoperative oedema
specifically that of lungs resulting in better oxygenation and
improved lung compliance postoperatively. Furthermore,
ultrafiltration may remove proinflammatory mediators from
the circulation such as IL-6 and IL-8 but it did not result in
significant improvement of clinical outcomes [73]. Similarly,
controlled haemodilution to regulate oncotic pressure can
reduce priming volumes and result in better haemodynamic
parameters such as vascular resistance and higher oxygen
delivery and affect hospital stay significantly [74, 75].
Understanding problems associated with pulmonary
ischaemia and reperfusion results in attempts to provide
continuous pulmonary perfusion during CPB. Experimen-
tal animal models of pulmonary perfusion demonstrated
reduced inflammatory and apoptosis pathways activation
with such strategy [25, 76, 77]. Moreover, pulmonary perfu-
sion was found to have favorable effect on lung compliance,
oxygenation, and vascular resistance in patients undergoing
CABG [78, 79]. Furthermore, pulmonary artery perfusion
during CPB can be effective in reducing postoperative right
ventricular dysfunction in high-risk patients undergoing
LVAD placement [80]. The translation of such changes
into better clinical outcomes remains unclear and may be
restricted to selective group of patients as demonstrated by
a recent trial in patients with COPD undergoing cardiac
surgery using CPB where no significant protective effect on
lungs was documented [81].
The deleterious effects of surface contact activation as
discussed previously have led to the development of min-
imised cardiopulmonary bypass circuit (mini-CPB). This
is characterised by reduced surface area and thus priming
volume and prevention of air-blood contact. The utilisation
ofmini-CPB has been shown to be associated with attenuated
production of proinflammatory cytokines and complement
activation and blunted leukocytes activation compared to
conventional circuit. Markers of oxidative stress tend to be
reduced in patients undergoing surgery using mini-CPB
compared to conventional circuit [82, 83]. Additionally,mini-
CPB reduces organ damage and results in better postoper-
ative gas exchange and lower lung injury scores [84, 85].
Unfortunately most of the clinical trials investigating the role
of mini-CPB have evaluated diverse technologies of varying
complexity and degree of miniaturisation, which would be
expected to give rise to heterogeneity in findings.
2.3. Surgical Strategies. It has been suggested that eliminating
the usual standard of no lung inflation during CPB by main-
taining a degree of lung ventilation may be beneficial. The
use of continuous positive airway pressure (CPAP) during
CPB may result in less shunt and better gas exchange [86];
however, it seems that such effect is dependent on the airway
pressure used. Using low frequency ventilation (LFV) along
with CPAP during CPB to reduce post-CPB lung injury has
been evaluated in an experimental pig model [87].This study
showed that the use of LFV is associated with significantly
better pulmonary gas exchange, higher adenine nucleotide,
lower LDH levels, and reduced histological damage in lung
biopsies aswell as lowerDNA levels in bronchoalveolar lavage
(BAL) compared to the collapsed lungs control group. How-
ever, a clinical study in patients undergoing cardiac surgery
compared the effect of low volume ventilation to conventional
strategy of no ventilation and demonstrated no significant
changes in PVRI, PaO(2)/FiO(2) ratio, postoperative length
of stay, and postoperative pulmonary complications [88].
Furthermore, a meta-analysis of 814 cases in 16 RCTs looking
at three lung protective strategies in patients during CPB
including CPAP, low-volume ventilation, and vital capacity
manoeuvres during CPB showed that the effects of the desig-
nated techniques are probably short lived with a questionable
impact on the long term clinical outcome of the treated
patients [89].
Off pump coronary artery bypass (OPCAB) surgery
seems to provide better lung protection by eliminating
ischemia-reperfusion injury throughmaintaining lung venti-
lation and avoiding CPB. Many studies consistently reported
better early and midterm outcomes in OPCAB when com-
pared with conventional on-pump CABG: fewer respiratory
complications, shorter intubation time and ITU stay, reduced
incidence of pneumonia, and overall shorter hospital stay
[90–92].
2.4. Physiotherapy. Preoperative prophylactic physiotherapy
with inspiratory or expiratory muscle training can be used
as a preventative measure for lung protection [93, 94]. Post-
operative physiotherapy is used prophylactically in patients
undergoing cardiac surgery. Different techniques can be
utilised during this period to improve ventilation-perfusion
inequalities, increase pulmonary compliance, and help rein-
flate collapsed alveoli.
These techniques include deep breathing exercises, slow
maximal inspirations with an inspiratory hold, intermittent
deep breathing exerciseswith andwithout the use of incentive
spirometer, and deep breathing exercises with expiratory
resistance [95–98].
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2.5. Postoperative Noninvasive Ventilation (NIV). NIV refers
to the administration of ventilatory support without using an
invasive artificial airway (endotracheal tube or tracheostomy
tube). NIV exerts its main effects on the pulmonary and
on the cardiovascular systems through the application of
a positive end-expiratory pressure (PEEP); with or without
a pressure support during inspiration, NIV restores lung
volumes by opening atelectatic areas, increases alveolar ven-
tilation, and reduces the work of breathing [99–101].
Continuous positive airway pressure (CPAP) aims to
maintain a level of positive airway pressure in a sponta-
neously breathing patient. It is functionally similar to positive
end-expiratory pressure (PEEP), except that PEEP is an
applied pressure against exhalation and CPAP is a pressure
applied by a constant flow. The ventilator does not cycle
during CPAP, no additional pressure above the level of CPAP
is provided, and patients must initiate all of their breaths.
To avoid drying of the respiratory mucosa, there has been
general agreement that the application of humidified CPAP
helps to recruit the lungs by increasing functional residual
capacity (FRC), increase the surface area of lung, decrease
intrapulmonary shunt, and improve oxygenation [102–104].
Bilevel positive airway pressure (BLPAP) is a continuous
positive airway pressure with pressure support breaths. It
delivers a preset inspiratory positive airway pressure (IPAP)
during inspiration and expiratory positive airway pressure
(EPAP). BLPAP can be described as CPAP with a time-
cycled or flow-cycled change of the applied pressure level
[105]. BLPAP senses patients breathing efforts by monitoring
air flow in the patient’s circuit and adjusts its output by
assisting inspiration. Therefore, its physiological effects can
benefit the patient in both phases of respiration [106–108].
BLPAP application can only be commenced on conscious,
cooperative, and hemodynamically stable patients who can
breathe spontaneously, have an adequate gag and cough
reflex, and are able to remove the mask when required.
Several studies have demonstrated beneficial effects of BLPAP
in reducing pulmonary complications and overall length of
hospital stay after cardiac surgery [109–111]. Furthermore, the
prophylactic use of BLPAP after early extubation has been
shown to be safe and effective [111, 112]. A better tolerance
was noted when BLPAP settings were commenced on low
level and gradually adjusted to achieve the therapeutic target.
Radiological improvement of atelectasis after cardiac surgery
has been achieved onmaintaining 8–10mL/kg of tidal volume
with BLPAP [113].
3. Conclusions
Pulmonary dysfunction is one of the most common and
serious complications after cardiac surgery and can signifi-
cantly impact on patient outcomes and health economics.The
mechanisms involved in the development of pulmonary dys-
function are multifactorial and are related to the activation of
different inflammatory and oxidative stress pathways. Clini-
cal manifestation varies from mild atelectasis to severe respi-
ratory failure. Managing pulmonary dysfunction postcardiac
surgery is a multistep process that starts before surgery
and continues during both the operative and postoperative
phases. Pulmonary protection strategies have evolved over
the years with various degrees of success. Themain weakness
of the majority of studies is often being observational in
nature, small sample size, or being concentrated on a single
intervention. Managing pulmonary dysfunction needs to be
a multistep process involving more than one modality for
each step of the surgical pathway. A better understanding
of available modalities and/or combinations will result in
the development of customised strategies for the different
cohorts of patients. This in turn will help reduce pulmonary
dysfunction and hence improve early outcome and costs after
cardiac surgery.
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